Unknown

Dataset Information

0

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

ABSTRACT:

SUBMITTER: Gunawan AS 

PROVIDER: S-EPMC5451352 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent <i>CSF3R</i> mutations in chronic neutrophilic leukemia.

Gunawan Arief S AS   McLornan Donal P DP   Wilkins Bridget B   Waghorn Katherine K   Hoade Yvette Y   Cross Nicholas C P NCP   Harrison Claire N CN  

Haematologica 20170316 6

Similar Datasets

Unknown Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
| S-EPMC7479634 | biostudies-literature
Unknown Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib.
| S-EPMC9504736 | biostudies-literature
Unknown Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
| S-EPMC3856962 | biostudies-literature
Unknown A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
| S-EPMC5927969 | biostudies-literature
Unknown Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
| S-EPMC3730275 | biostudies-literature
Unknown Changes in allele frequencies of <i>CSF3R</i> and <i>SETBP1</i> mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.
| S-EPMC5477626 | biostudies-literature
Unknown Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?
| S-EPMC10567908 | biostudies-literature
Unknown The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes.
| S-EPMC7189991 | biostudies-literature
Unknown A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
| S-EPMC4231215 | biostudies-literature
Unknown A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
| S-EPMC8170698 | biostudies-literature